Petrus Jansen - Carmat Medical Director
| ALCAR Stock | EUR 0.97 0.03 3.00% |
Director
Dr. Petrus Jansen was the Medical Director of Carmat SA since December 2009. Dr. Jansen has held manager positions at medical device companies focused on Circulatory Support since 1997. He was Chief Medical Officer at World Heart Corporation in Oakland CA, USA from 2004 to 2009. Dr. Jansen was Vice President, Clinical Programs at Orqis International GmbH from 2003 to 2004 Vice President, Clinical Affairs at Jarvik Heart Inc. from 2001 to 2003. From 1997 to 2001, Dr. Jansen worked for the Novacor Division of Edwards Lifesciences LLC, formerly Baxter Corporationrationration. Prior to joining the medical device industry, he worked multiple years in cardiac surgery clinics in Amsterdam, the Netherlands since 2009.
| Tenure | 15 years |
| Phone | 33 1 39 45 64 50 |
| Web | https://www.carmatsa.com |
Carmat Management Efficiency
The company has return on total asset (ROA) of (0.3856) % which means that it has lost $0.3856 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.5378) %, meaning that it generated substantial loss on money invested by shareholders. Carmat's management efficiency ratios could be used to measure how well Carmat manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | DIRECTOR Age | ||
| David Sourdive | Cellectis | 56 | |
| Daniel Soland | DBV Technologies SA | 61 | |
| Claire Giraut | DBV Technologies SA | 63 | |
| Julie ONeill | DBV Technologies SA | 53 | |
| Lucie Mondoulet | DBV Technologies SA | N/A | |
| Michael Goller | DBV Technologies SA | 44 | |
| Viviane Monges | DBV Technologies SA | 55 | |
| Torbjorn Bjerke | DBV Technologies SA | 57 | |
| Mailys Ferrere | DBV Technologies SA | 56 | |
Management Performance
| Return On Equity | -2.54 | |||
| Return On Asset | -0.39 |
Carmat Leadership Team
Elected by the shareholders, the Carmat's board of directors comprises two types of representatives: Carmat inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carmat. The board's role is to monitor Carmat's management team and ensure that shareholders' interests are well served. Carmat's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carmat's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Petrus Jansen, Medical Director | ||
| Francesco Arecchi, Director of Marketing | ||
| Eric Richez, Director of Business Development | ||
| Stephane Piat, CEO, Director | ||
| Raouia Bouyanzer, Director of Human Resources | ||
| Pascale dArbonneau, Chief Financial and Administrative Officer |
Carmat Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Carmat a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.54 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (21.94) % | |||
| Current Valuation | 218.78 M | |||
| Shares Outstanding | 22.67 M | |||
| Shares Owned By Insiders | 42.90 % | |||
| Shares Owned By Institutions | 2.28 % | |||
| Price To Earning | (6.35) X | |||
| Price To Book | 1,235 X | |||
| Price To Sales | 87.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Carmat Stock Analysis
When running Carmat's price analysis, check to measure Carmat's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmat is operating at the current time. Most of Carmat's value examination focuses on studying past and present price action to predict the probability of Carmat's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmat's price. Additionally, you may evaluate how the addition of Carmat to your portfolios can decrease your overall portfolio volatility.